Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 8:14:1190235.
doi: 10.3389/fimmu.2023.1190235. eCollection 2023.

Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review

Heba M Bintalib  1   2   3 , Annick van de Ven  4 , Joseph Jacob  1   5 , Jesper Rømhild Davidsen  6   7 , Børre Fevang  8   9 , Leif G Hanitsch  10   11 , Marion Malphettes  12 , Joris van Montfrans  13 , Paul J Maglione  14 , Cinzia Milito  15 , John Routes  16 , Klaus Warnatz  17   18 , John R Hurst  1
Affiliations

Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review

Heba M Bintalib et al. Front Immunol. .

Abstract

Introduction: Common variable immunodeficiency related interstitial lung disease (CVID-ILD, also referred to as GLILD) is generally considered a manifestation of systemic immune dysregulation occurring in up to 20% of people with CVID. There is a lack of evidence-based guidelines for the diagnosis and management of CVID-ILD.

Aim: To systematically review use of diagnostic tests for assessing patients with CVID for possible ILD, and to evaluate their utility and risks.

Methods: EMBASE, MEDLINE, PubMed and Cochrane databases were searched. Papers reporting information on the diagnosis of ILD in patients with CVID were included.

Results: 58 studies were included. Radiology was the investigation modality most commonly used. HRCT was the most reported test, as abnormal radiology often first raised suspicion of CVID-ILD. Lung biopsy was used in 42 (72%) of studies, and surgical lung biopsy had more conclusive results compared to trans-bronchial biopsy (TBB). Analysis of broncho-alveolar lavage was reported in 24 (41%) studies, primarily to exclude infection. Pulmonary function tests, most commonly gas transfer, were widely used. However, results varied from normal to severely impaired, typically with a restrictive pattern and reduced gas transfer.

Conclusion: Consensus diagnostic criteria are urgently required to support accurate assessment and monitoring in CVID-ILD. ESID and the ERS e-GLILDnet CRC have initiated a diagnostic and management guideline through international collaboration.

Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022276337.

Keywords: CVID; GLILD; diagnosis; interstitial lung disease; systematic review.

PubMed Disclaimer

Conflict of interest statement

AV reports fees for educational activities from Takeda outside the submitted work.JJ reports fees from Boehringer Ingelheim, Roche, NHSX, Takeda and GlaxoSmithKline unrelated to the submitted work. JJ was supported by Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z and the NIHR Biomedical Research Centre at University College London.JD reports fees for advisory board meetings, teaching and educational activities, and congress participation from Boehringer Ingelheim outside the submitted work.PM has received grant support from the National Institutes of Health, AAAAI Foundation, Immune Deficiency Foundation, Takeda, Horizon Pharma, and Boston University and has received consulting fees from Medscape and Pharming.KW reports honoraria for advisory board meetings, teaching and educational activities from TAKEDA, LFB biomedicaments, CSL Behring, Grifols, and Bristol-Myers Squibb outside the submitted work. In addition, KW has received a research grant by Bristol-Myers Squibb for the investigation of Abatacept for interstitial lung disease in CVID.JH has received support to attend meetings, personal payment and payment to his employer from companies that make medicines to treat respiratory disease and immunoglobulin products. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram of study selection process. From: (11). For more information, visit: http://www.prisma-statement.org/.
Figure 2
Figure 2
Images of two patients. Left: diffuse nodules and lymphadenopathy. Right: combination of diffuse nodules, reticulation and ground-glass opacities. Apart from CVID-ILD features, there are also signs of airway disease. From reference (51) with permission.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, et al. . International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract (2016) 4(1):38–59. doi: 10.1016/j.jaip.2015.07.025 - DOI - PMC - PubMed
    1. Fraz MSA, Michelsen AE, Moe N, Aaløkken TM, Macpherson ME, Nordøy I, et al. . Raised serum markers of T cell activation and exhaustion in granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency. J Clin Immunol (2022) 42:1–11. doi: 10.1007/s10875-022-01318-1 - DOI - PMC - PubMed
    1. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol (2010) 137(1):21–30. doi: 10.1016/j.clim.2010.06.012 - DOI - PubMed
    1. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood (2012) 119(7):1650–7. doi: 10.1182/blood-2011-09-377945 - DOI - PMC - PubMed
    1. Bates CA, Ellison MC, Lynch DA, Cool CD, Brown KK, Routes JM. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol (2004) 114(2):415–21. doi: 10.1016/j.jaci.2004.05.057 - DOI - PubMed

Publication types

MeSH terms